Renee-Claude Mercier, PharmD

Gilead Sciences, Inc.
Foster City, California, United States

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT